Drug-induced valvulopathy: An update

Toxicologic Pathology

Volumn 38, Issue 6, 2010, Pages 837-848

  Elangbam, Chandikumar S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

5 hydroxytryptamine 2B receptor; animal models; anorexigens; ergot alkaloids; heart valve; valvulopathy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; DIHYDROERGOTAMINE; ERGOTAMINE; FENFLURAMINE; GLYCOSAMINOGLYCAN; LISURIDE; METHYLERGOMETRINE; METHYSERGIDE; NORFENFLURAMINE; PERGOLIDE; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE; SEROTONIN 2B RECEPTOR; TERGURIDE;

DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; HUMAN; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VALVULAR HEART DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; APPETITE DEPRESSANTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FENFLURAMINE; HEART VALVES; HUMANS; MYOFIBROBLASTS; PERGOLIDE; RECEPTOR, SEROTONIN, 5-HT2B;

ANIMALIA;

EID: 78649922972     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310378027     Document Type: Review

References (109)

1. Aikawa, E., Whittaker, P., Farber, M., Mendelson, K., Padera, R.F., Aikawa, M., and Schoen, F.J. (2006). Human semilunar cardiac valve remodelling by activated cells from fetus to adult: Implications of postnatal adaptation, pathology, and tissue engineering. Circulation 113, 1344-52.
2. Antonini, A., and Poewe, W. (2007). Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6, 826-29.
3. Aupperle, H., Marz, I., Thielebein, J., Dinges, G., and Schoon, H.A. (2010). Histomorphological findings and expression of matrix metalloproteinases and their tissue specific inhibitors (TIMPs) in normal tricuspid valves and in chronic tricuspid valvular disease in dogs. Vet J 183, 176-83.
4. Aupperle, H., Marz, I., Thielebein, J., Kiefer, B., Dinges, G., and Schoon, H. (2009). Distribution of extracellular matrix components in normal and degenerated canine tricuspid valve leaflets. J Comp Pathol 141, 41-51.
5. Aupperle, H., Thielebein, J., Kiefer, B., Marz, I., Dinges, G., and Schoon, H.A. (2009). An immunohistochemical study of the role of matrix metalloproteinases and their tissue inhibitors in chronic mitral valvular disease (valvular endocardiosis) in dogs. Vet J 180, 88-94.
6. Bana, D.S., MacNeal, P.S., LeCompte, P.M., Shah, Y., and Graham, J.R. (1974). Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88, 640-55.
7. Baseman, D.G., O'Suilleabhain, P.E., Reimold, S.C., Laskar, S.R., Baseman, J.G., and Dewey, R.B. (2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63, 301-4.
8. Bigal, M., Liberman, J.N., and Lipton, R.B. (2006). Age-dependent prevalence and clinical features of migraine. Neurology 67, 246-51.
9. Bowen, R., Glicklich, A., Khan, M., Rasmussen, S., Wadden, T., Bustad, J., Graham, D., Green, L., Lumpkin, M., O'Neill, R., Sobel, S., Hubbard, V.S., Yanovski, S., and Sopko, G. (1997). Cardiac valvulopathy associated with exposure fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations. JAMA 278, 1729-31.
10. Bratter, J., Gessner, I.H., and Rowland, N.E. (1999). Effects of prenatal coadministration of phentermine and dexfenfluramine in rats. Eur J Pharmacol 369, R1-3.
11. Butcher, J.T., Tressel, S., Johnson, T., Turner, D., Sorescu, G., Jo, H., and Nerem, R.M. (2006). Transcriptional profiles of valvular and vascular endothelial cell reveal phenotypic differences: influence of shear stress. Arterioscler Thromb Vasc Biol 26, 69-77.
12. Carabello, B.A., and Crawford, F.A. (1997). Valvular heart disease. N Engl J Med 337, 32-41.
13. Chen, J., Yip, C.Y.Y., Sone, E.D., and Simmons, C.A. (2009). Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 174, 1109-19.
14. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., and Schaff, H.V. (1997). Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337, 581-88.
15. Connolly, J.M., Bakay, M.A., Fulmer, J.T., Gorman, R.C., Gorman III, J.H., Oyama, M.A., and Levy, R.J. (2009). Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. Am J Pathol 175, 988-97.
16. Cushing, M.C., Liao, J.T., and Anseth, K.S. (2005). Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. Matrix Biol 24, 428-37.
17. Dahl, C.F., Allen, M.R., Urie, P.M., and Hopkins, P.N. (2008). Valvular regurgitation and surgery associated with fenfluramine use: An analysis of 5743 individuals. BMC Medicine 6, 34.
18. Desmouliere, A., Chaponnier, C., and Gabbiani, G. (2005). Tissue repair, contraction, and the myofibroblast. Wound Rep Reg 13, 7-12.
19. Donnelly, K.B. (2008). Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases. Toxicol Pathol 36, 204-17.
20. Droogmans, S., Cosyns, B., D'haenen, H., Creeten, E., Weytjens, C., Franken, P.R., Scott, B., Schoors, D., Kemdem, A., Close, L., Vandenbossche, J.L., Bechet, S., and Van Camp, G. (2007). Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100, 1442-45.
21. Droogmans, S., Franken, P.R., Garbar, C., Weytjens, C., Cosyns, B., Lahoutte, T., Caveliers, V., Pipeleers-Marichal, M., Bossuyt, A., Schoors, D., and Van Camp, G. (2007). In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 28, 2156-62.
22. Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M., Franken, P.R., Lahoutte, T., Schoors, D., and Van Camp, G. (2009). Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am J Physiol Heart Circ Physiol 296, H1940-48.
23. Elangbam, C.S., Job, L.E., Zadrozny, L.M., Barton, J.C., Yoon, L.W., Gates, L.D., and Slocum, N. (2008). 5-Hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60, 253-62.
24. Elangbam, C.S., Lightfoot, R.L., Yoon, L.W., Creech, D.R., Geske, R.S., Crumbley, C.W., Gates, L., and Wall, H.G. (2005). 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53, 671-77.
25. Elangbam, C.S., Wehe, J.G., Barton, J.C., Krull, D.L., Nyska, A., Crabbs, T.A., and Kissling, G. (2006). Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in rat heart valves with spontaneous mitral valvulopathy-a possible exacerbation by dl, amphetamine sulfate in Fischer rats. Exp Toxicol Pathol 58, 89-99.
26. European Medicines Agency (EMEA). (2008). Questions and answers on the review of ergot-derived dopamine agonists. EMEA http://www.emea.europa.eu/pdfs/ general/direct/pr/31905408en.pdf
27. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2005). Annual Report 2005: The State of the Drugs Problem in Europe. EMCDDA http://annualreport.emcdda.eu.int
28. Fanburg, B.L., and Lee, S.L. (1997). A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272, L795 - L806.
29. Fayet, C., Bendeck, M.P., and Gotlieb, A.I. (2007). Cardiac valve interstitial cells secrete fibronectin and form fibrillar adhesions in response to injury. Cardiovasc Pathol 16, 203-11.
30. Fishman, A.P. (1999). Aminorex to Fen/Phen. An epidemic foretold. Circulation 99, 156-61.
31. Fitzgerald, L.W., Burn, T.C., Brown, B.S., Patterson, J.P., Corjay, M.H., Valentine, P.A., Sun, J.H., Link, J.R., Abbaszade, I., Hollis, J.M., Largent, B.L., Hartig, P.R., Hollis, G.F., Meunier, P.C., Robichaud, A.J., and Robertson, D.W. (2000). Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57, 75-81.
32. Gordon, K.J., and Blobe, G.C. (2008). Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim Biophys Acta 1782, 197-228.
33. Graham, J.R. (1967). Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 254, 1-12.
34. Grande-Allen, K.J., Calabro, A., Gupta, V., Wight, T.N., Hascall, V.C., and Vesely, I. (2004). Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. Glycobiology 14, 621-33.
35. Greaves, P. (2007). Cardiovascular system. In Histopathology of Preclinical Toxicity Studies - interpretation and relevance in drug safety evaluation (P. Greaves, ed.). pp. 270-333. Elsevier, New York.
36. Greffe, G., Chalabreysse, L., Mouly-Bertin, C., Lantelme, P., Thivolet, F., Aulagner, G., and Obadia, J.F. (2007). Valvular heart disease associated with fenfluramine detected 7 years after discontinuation of treatment. Ann Thorac Surg 83, 1541-43.
37. Gupta, V., Barzilla, J.E., Mendez, J.S., Stephens, E.H., Lee, E.L., Collard, C.D., Laucirica, R., Weigel, P.H., and Grande-Allen, K.J. (2008). Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 18, 191-97.
38. Gustafsson, B.I., Tommeras, K., Nordrum, I., Loennechen, J.P., Brunsvik, A., Solligard, E., Fossmark, R., Bakke, I., Syversen, U., and Waldum, H. (2005). Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517-22.
39. Hauck, A.J., Edwards, W.D., Danielson, G.K., Mullany, C.J., and Bresnahan, D.R. (1990). Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. Arch Pathol Lab Med 114, 62-64.
40. Heldin, C.H., Miyazono, K., and ten Dijke, P. (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-71.
41. Hendrikx, M., Van Dorpe, J., Flameng, W., and Daenen, W. (1996). Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 5, 235-37.
42. Hershel, J. (2000). Heart valve disorders and appetite-suppressant drugs. JAMA 283, 1738-40.
43. Hinz, B., Phan, S.H., Thannickal, V.J., Galli, A., Bochaton-Piallat, M., and Gabbiani, G. (2007). The myofibroblast: one function, multiple origins. Am J Pathol 170, 1807-16.
44. Huang, X., Setola, V., Yadav, P.N., Allen, J.A., Rogan, S.C., Hanson, B.J., Revankar, C., Robers, M., Doucette, C., and Roth, B.L. (2009). Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: Implications for drug safety assessment. Mol Pharmacol 76, 710-22.
45. Ignotz, R.A., and Massague, J. (1986). Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261, 4337-45.
46. Jahnichen, S., Horowski, R., and Pertz, H.H. (2005). Agonism at 5HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513, 225-28.
47. Jian, B., Xu, J., Connolly, J., Savani, R.C., Narula, N., Liang, B., and Levy, R.J. (2002). Serotonin mechanisms in heart valve disease I: Serotonin-induced up-regulation of transforming growth factor-β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161, 2111-21.
48. Jick, H., Vasilakis, C., Weinrauch, L.A., Meier, C.R., Jick, S.S., and Derby, L.E. (1998). A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339, 719-24.
49. Jollis, J.G., Landolfo, C.K., Kisslo, J., Constantine, G.D., Davis, K.D., and Ryan, T. (2000). Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101, 2071-77.
50. Kassiri, Z., and Khokha, R. (2005). Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. J Throm Haemost 93, 212-19.
51. Keane, J.F., Driscoll, D.J., Gersony, W.M., Hayes, C.J., Kidd, L., O' Fallon, W.M., Pieroni, D.R., Wolfe, R.R., and Weidman, W.H. (1993). Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 87, 16-27.
52. Kinsella, M.G., Bressler, S.L., and Wight, T.N. (2004). The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr 14, 203-34.
53. Kresse, H., and Schonherr, E. (2001). Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189, 266-74.
54. Li, Y.Y., McTiernan, C.F., and Feldman, A.M. (2000). Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 214-24.
55. Liu, A.C., and Gotlieb, A.I. (2008). Transforming growth factor-β regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 173, 1275-85.
56. Liu, A.C., Joag, V.R., and Gotlieb, A.I. (2007). The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 171, 1407-18.
57. Lopez-Ilasaca, M. (1998). Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 56, 269-77.
58. Mahimkar, R., Nguyen, A., Mann, M., Yeh, C.C., Zhu, B.Q., Karliner, J.S., and Lovett, D.H. (2009). Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol 18, 253-61.
59. Marron, K., Yacoub, M.H., Polak, J.M., Sheppard, M.N., Fagan, D., Whitehead, B.F., de Leval, M.R., Anderson, R.H., and Wharton, J. (1996). Innervation of human atrioventricular and arterial valves. Circulation 94, 368-75.
60. Martins, S.S., Mazzotti, G., and Chilcoat, H.D. (2005). Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use. Exp Clin Psychopharmacol 13, 244-52.
61. Massague, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. Genes Dev 19, 2783-810.
62. Maxie, M.G., and Robinson, W.F. (2007). Cardiovascular system. In Jubb, Kennedy and Palmer's Pathology of Domestic Animals (M. G. Maxie, ed.). pp. 1-105. Elsevier Saunders, Philadelphia, PA.
63. McDonald, P.C., Wilson, J.E., Gao, M., McNeill, S., Spinelli, J.J., Williams, O.D., Harji, S., Kenyon, J., and McManus, B.M. (2002). Quantitative analysis of human heart valves-Does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 11, 251-62.
64. Mekontso-Dessap, A., Brouri, F., Pascal, O., Lechat, P., Hanoun, N., Lanfumey, L., Seif, I., Benhaiem-Sigaux, N., Kirsch, M., Hamon, M., Adnot, S., and Eddahibi, S. (2006). Deficiency in the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81-89.
65. Messier, R.H., Bass, B.L., Aly, H.M., Jones, J.L., Domkowski, P.W., Wallace, R.B., and Hopkins, R.A. (1994). Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res 57, 1-21.
66. Millan, M.J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.A., and Newman-Tancredi, A. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmcol Exp Ther 303, 791-804.
67. Misch, K.A. (1974). Development of heart valve lesions during methysergide therapy. Br Med J 2, 365-66.
68. Mulholland, D.L., and Gotlieb, A.I. (1996). Cell biology of valvular interstitial cells. Can J Cardiol 12, 231-36.
69. Mulholland, D.L., and Gotlieb, A.I. (1997). Cardiac valve interstitial cells: regulator of valve structure and function. Cardiovasc Pathol 6, 167-74.
70. National Toxicology Program (NTP) (1991). NTP Technical Report on the Toxicology and Carcinogenesis Studies of dl-Amphetamine Sulfate (CAS No. 60-13-9) in F344/N Rats and B6C3F1 Mice (Feed Studies). NTP TR-387, NIEHS, Research Triangle Park, NC ( http://ntp-server.niehs.nih.gov/index ).
71. Nichols, D.E., and Nichols, C.D. (2008). Serotonin receptors. Chem Rev 108, 1614-41.
72. Norris, R.A., Moreno-Rodriguez, R.A., Sugi, Y., Hoffman, S., Amos, J., Hart, M.M., Potts, J.D., Goodwin, R.L., and Markwald, R.R. (2008). Periostin regulates atrioventricular valve maturation. Dev Biol 316, 200-13.
73. Pena-Silva, R.A., Miller, J.D., Chu, Y., and Heistad, D.D. (2009). Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am J Physiol 297, H1354-60.
74. Plendl, J. (2006). Cardiovascular system. In Dellmann's Textbook of Veterinary Histology (J. A. Eurell and B. L. Frappier, eds.). pp. 117-33. Black-well Publishing Professional, Ames, IA.
75. Pritchett, A.M., Morrison, J.F., Edwards, W.D., Schaff, H.V., Connolly, H.M., and Espinosa, R.E. (2002). Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77, 1280-86.
76. Rabkin, E., Aikawa, M., Stone, J.R., Fukumoto, Y., Libby, P., and Schoen, F.J. (2001). Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104, 2525-32.
77. Rajamannan, N.M., Caplice, N., Anthikad, F., Sebo, T.J., Orszulak, T.A., Edwards, W.D., Tajik, J., and Schwartz, R.S. (2001). Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10, 827-31.
78. Redfield, M.M., Nicholson, W.J., Edwards, W.D., and Tajik, A.J. (1992). Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med 117, 50-52.
79. Reed, C.C., and Iozzo, R.V. (2002). The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19, 249-55.
80. Roth, B.L. (2007). Drugs and valvular heart disease. N Engl J Med 356, 6-9.
81. Rothman, R.B., and Baumann, M.H. (2009). Appetite suppressants, Cardiac valve disease and combination pharmacotherapy. Am J Ther 16, 354-64.
82. Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, S.J., and Roth, B.L. (2000). Evidence for possible involvement of 5HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 101, 2836-41.
83. Roy, A., Brand, N.J., and Yacoub, M.H. (2000). Molecular characterization of interstitial cells isolated from human heart valves. J Heart Valve Dis 9, 459-64.
84. Sachdev, M., Miller, W.C., Ryan, T., and Jollis, J.G. (2002). Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 144, 1065-73.
85. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., and Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356, 29-38.
86. Schoen, F.J. (2005 a). Cardiac valves and valvular pathology-Update on function, disease, repair, and replacement. Cardiovasc Pathol 14, 189-94.
87. Schoen, F.J. (2005 b). The heart. In Robbins and Cotran Pathologic Basis of Disease (V. Kumar, A. K. Abbas, and N. Fausto, eds.). pp. 555-618. Elsevier Saunders, Philadelphia.
88. Schoen, F.J. (2006). New frontiers in the pathology and therapy of heart valve disease: 2006 Society for Cardiovascular Pathology, Distinguished Achievement Award Lecture, United States-Canadian Academy of Pathology. Cardiovasc Pathol 15, 243-51.
89. Schoen, F.J., and Edwards, W.D. (2001). Valvular heart disease: General principles and stenosis. In Cadiovascular Pathology (M. D. Silver, A. I. Gotlieb, and F. J. Schoen, eds.). pp. 402-42. Churchill Livingstone, Philadelphia.
90. Serratrice, J., Disdier, P., Habib, G., Viallet, F., and Weiller, P.J. (2002). Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10, 334-36.
91. Setola, V., and Roth, B.L. (2005). Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on "fenphen. " Exp Opin Drug Metab Toxicol 1, 377-87.
92. Setola, V., Hufeisen, S.J., GrandeAllen, K.J., Vesely, I., Glennon, R.A., Blough, B., Rothman, R.B., and Roth, B.L. (2003). 3,4-Methylenediox ymethamphetamine (MDMA, "ecstasy") induces fenfluramine-like proliferative actions of human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63, 1223-29.
93. Simmons, C.A., Grant, G.R., Manduchi, E., and Davies, P.F. (2005). Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 96, 792-99.
94. SoRelle, R. (1999). Diet drug maker agrees to $3.75 billion settlement. Circulation 100, 133-34.
95. Steffee, C.H., Singh, H.K., and Chitwood, W.R. (1999). Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8, 245-53.
96. Steiger, M., Jost, W., Grandas, F., and Van Camp, F. (2009). Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 116, 179-91.
97. Taylor, P.M., Allen, S.P., and Yacoub, M.H. (2000). Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J Heart Valve Dis 9, 150-58.
98. Thom, T., Haase, N., Rosamond, W., Howard, V.J., Rumsfeld, J., Manolio, T., Zheng, Z.J., Flegal, K., O'Donnell, C., Kittner, S., Lloyd-Jones, D., Goff Jr., D.C., Hong, Y., Adams, R., Friday, G., Furie, K., Gorelick, P., Kissela, B., Marler, J., Meigs, J., Roger, V., Sidney, S., Sorlie, P., Steinberger, J., Wasserthiel-Smoller, S., Wilson, M., and Wolf, P. (2006). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, e85 - e151.
99. Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., and Schoors, D. (2004). Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179-83.
100. Van Vleet, J.F., Ferrans, V.J., and Herman, E. (2002). Cardiovascular and skeletal muscle systems. In Handbook of Toxicologic Pathology (W. M. Haschek, C. G. Rousseaux, and M. A. Wallig, eds.). pp. 363-455. Academic Press, San Diego, CA.
101. Visconti, R.P., Ebihara, Y., LaRue, A.C., Fleming, P.A., McQuinn, T.C., Masuya, M., Minamiguchi, H., Markwald, R.R., Ogawa, M., and Drake, C.J. (2006). An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res 98, 690-96.
102. Visse, R., and Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 92, 827-39.
103. Volmar, K.E., and Hutchins, G.M. (2001). Aortic and mitral fenfluramine- phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125, 1555-61.
104. Walker, G.A., Masters, K.S., Shah, D.N., Anseth, K.S., and Leinwand, L.A. (2004). Valvular myofibroblast activation by transforming growth factor-β: implications for pathological extracellular matrix remodelling in heart valve disease. Circ Res 95, 253-60.
105. Waltenberger, J., Lundin, L., Oberg, K., Wilander, E., Miyazono, K., Heldin, C.H., and Funa, K. (1993). Involvement of transforming growth factor-β in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142, 71-78.
106. Wight, T.N. (2002). Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14, 617-23.
107. Wight, T.N., Heinegard, D., and Hascall, V.C. (1991). Proteoglycans: structure and function. In Cell Biology of Extracellular Matrix (E.D. Hay, ed.). pp. 45-78. Plenum Press, New York.
108. Yanovski, S.Z., and Yanovski, J.A. (2002). Obesity. N Engl J Med 346, 591-602.
109. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., and Pezzoli, G. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356, 39-46.